AK-106-001616

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAK-106-001616
Drug Alias NameAK-106AK106-001616
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytosolic phospholipase A2 inhibitors
TargetsCytosolic phospholipase A2
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUkraineSlovakia +[9
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAsahi Kasei Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A